Institut Gustave Roussy

Site:	Institut Gustave Roussy	Go to their website
Address:
City:	Villejuif
State:	Val de Narne
Zip:	94805
Country:	France

34 trials at this site

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
1	Imatinib + IL-2	Ongoing, but not recruiting	Closed	Imatinib + IL-2
1	A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Ongoing, but not recruiting	Closed	GDC-0980	NCT00854126
1	Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers	Completed	Closed	Masitinib, (AB1010)
1	Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BEZ235 + MEK162	NCT01337765
1	A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BKM120	NCT01468688
1	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Active, not recruiting	Closed	BLU-285	NCT02508532
1	A Study of NB003 in Patients With Advanced Malignancies	Recruiting	Not yet activated	NB003	NCT04936178
2	Masitinib in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)	Unknown	Closed	Masitinib, (AB1010)	NCT00998751
2	A Study of R1507 in Patients With Recurrent or Refractory Sarcoma	Does not allow GIST	Closed	R1507	NCT00642941
2	Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00568750
2	A phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib	Unknown	Closed	Masitinib, (AB1010)	NCT01506336
2	Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)	Completed	Closed	Pazopanib (Votrient)	NCT01323400
2	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ongoing, but not recruiting	Closed	MEK162 + BYL719	NCT01449058
2	Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST)	Ongoing, but not recruiting	Closed	Palbociclib	NCT01907607
2	A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)	Unknown	Active	Imatinib + Regorafenib	NCT02365441
2	Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)	Active, not recruiting	Not yet activated	Pembrolizumab + Cyclophosphamide	NCT02406781
2	Ph II CABOGIST in GIST	Active, not recruiting	Closed	Cabozantinib	NCT02216578
2	Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)	Recruiting	Not yet activated	Imatinib	NCT05009927
2	A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)	Recruiting	Active	Imatinib + Atezolizumab	NCT05152472
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075

Institut Gustave Roussy

34 trials at this site

Page 1 of 2 | Next | Last